Objective:Pancreatic ductal adenocarcinoma cancer(PDAC)is one of the leading causes of cancer-related death worldwide.Hence,the development of effective anti-PDAC therapies is urgently required.Patient-derived xenogra...Objective:Pancreatic ductal adenocarcinoma cancer(PDAC)is one of the leading causes of cancer-related death worldwide.Hence,the development of effective anti-PDAC therapies is urgently required.Patient-derived xenograft(PDX)models are useful models for developing anti-cancer therapies and screening drugs for pre&sion medicine.This review aimed to provide an updated summary of using PDX models in PDAC.Data sources:The author retrieved information from the PubMed database up to June 2019 using various combinations of search terms,including PDAC,pancreatic carcinoma,pancreatic cancer,patient-derived xenografts or PDX,and patient-derived tumor xenografts or PDTX.Study selection:Original articles and review articles relevant to the review's theme were selected.Results:PDX models are better than cell line-derived xenograft and other models.PDX models consistently demonstrate retained tumor morphology and genetic stability,are benefi&al in cancer research,could enhance drug discovery and oncologic mechanism development of PDAC,allow an improved understanding of human cancer cell biology,and help guide personalized treatmem.Conclusions:In this review,we outline the status and application of PDX models in both basic and pre-clinical pancreatic cancer researches.PDX model is one of the most appropriate pre-clinical tools that can improve the prognosis of patients with pancreatic cancer in the future.展开更多
文摘Objective:Pancreatic ductal adenocarcinoma cancer(PDAC)is one of the leading causes of cancer-related death worldwide.Hence,the development of effective anti-PDAC therapies is urgently required.Patient-derived xenograft(PDX)models are useful models for developing anti-cancer therapies and screening drugs for pre&sion medicine.This review aimed to provide an updated summary of using PDX models in PDAC.Data sources:The author retrieved information from the PubMed database up to June 2019 using various combinations of search terms,including PDAC,pancreatic carcinoma,pancreatic cancer,patient-derived xenografts or PDX,and patient-derived tumor xenografts or PDTX.Study selection:Original articles and review articles relevant to the review's theme were selected.Results:PDX models are better than cell line-derived xenograft and other models.PDX models consistently demonstrate retained tumor morphology and genetic stability,are benefi&al in cancer research,could enhance drug discovery and oncologic mechanism development of PDAC,allow an improved understanding of human cancer cell biology,and help guide personalized treatmem.Conclusions:In this review,we outline the status and application of PDX models in both basic and pre-clinical pancreatic cancer researches.PDX model is one of the most appropriate pre-clinical tools that can improve the prognosis of patients with pancreatic cancer in the future.
